Hormone-Resistant Prostate and Breast Cancers Added to Clinical Study Based on Encouraging Preliminary Results
August 11, 2021CureLab Oncology Presents at 2021 ESMO Congress
BOSTON – September 16, 2021: CureLab Oncology’s a clinical-stage biotech company, is presenting at this year’s European Society for Medical Oncology. Two reports were accepted and are featured as e-posters in the oncology/PRO educational portal for oncologists.
The reports describe findings resulting from CureLab’s clinical trials of Elenagen™, an experimental DNA therapy, that are currently underway at N.N. Alexandrov National Cancer Centre of Belarus under the direction of a team led by Deputy Director Professor Sergei Krasny, MD, DSc.
The reports are available online:
- Plasmid encoding p62/SQSTM1 administered in combination with CMF chemotherapy improves outcomes in metastatic triple-negative breast cancer patients
- Adding dosing of plasmid encoding p62/SQSTM1 to gemcitabine chemotherapy may provide clinical benefits to patients with platinum-resistant ovarian cancer
CureLab’s lead investigational compound is code-named Elenagen, an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1. In animal studies and Phase I/II human trials conducted ex-US, Elenagen has shown promise in reversing tumor grade, changing the tumor microenvironment, and enhancing the anti-cancer effects of chemotherapy. Experimental results indicate a mitigation of chronic inflammation and stimulation of an immune response to the tumor.
CureLab Oncology Inc. is a pre-IPO, clinical-stage immuno-oncology biotech company headquartered in the greater Boston area. CureLab is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications. To learn more, visit curelaboncology.com.
Tim Cox, ZingPR, tim@zingpr.com
